Bank of New York Mellon
STOK icon

Bank of New York Mellon’s Stoke Therapeutics STOK Stock Holding History

Bank of New York Mellon’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38M Buy
164,273
+20,866
+15% +$670K ﹤0.01% 2401
2026
Q1 		$4.67M Buy
143,407
+2,605
+2% +$85.4K ﹤0.01% 2351
2025
Q4 		$4.47M Buy
140,802
+20,366
+17% +$612K ﹤0.01% 2385
2025
Q3 		$2.83M Buy
120,436
+16,663
+16% +$286K ﹤0.01% 2631
2025
Q2 		$1.18M Buy
103,773
+13,788
+15% +$131K ﹤0.01% 3049
2025
Q1 		$598K Sell
89,985
-3,210
-3% -$29.9K ﹤0.01% 3356
2024
Q4 		$1.03M Buy
93,195
+1,330
+1% +$16.3K ﹤0.01% 3148
2024
Q3 		$1.13M Sell
91,865
-24,027
-21% -$340K ﹤0.01% 3072
2024
Q2 		$1.57M Buy
115,892
+25,988
+29% +$351K ﹤0.01% 2937
2024
Q1 		$1.21M Sell
89,904
-8,424
-9% -$51K ﹤0.01% 3044
2023
Q4 		$517K Sell
98,328
-8,926
-8% -$38.2K ﹤0.01% 3533
2023
Q3 		$423K Buy
107,254
+2,926
+3% +$19.2K ﹤0.01% 3639
2023
Q2 		$1.11M Buy
104,328
+14,746
+16% +$157K ﹤0.01% 3138
2023
Q1 		$746K Sell
89,582
-1,193
-1% -$10.8K ﹤0.01% 3272
2022
Q4 		$838K Buy
90,775
+10,595
+13% +$110K ﹤0.01% 3279
2022
Q3 		$1.03M Buy
80,180
+8,556
+12% +$136K ﹤0.01% 3189
2022
Q2 		$947K Buy
71,624
+8,926
+14% +$136K ﹤0.01% 3240
2022
Q1 		$1.32M Buy
62,698
+837
+1% +$16.8K ﹤0.01% 3143
2021
Q4 		$1.48M Buy
61,861
+1,924
+3% +$45.9K ﹤0.01% 3159
2021
Q3 		$1.52M Buy
59,937
+5,565
+10% +$155K ﹤0.01% 3164
2021
Q2 		$1.83M Buy
54,372
+3,192
+6% +$113K ﹤0.01% 3041
2021
Q1 		$1.99M Sell
51,180
-3,055
-6% -$174K ﹤0.01% 2928
2020
Q4 		$3.36M Buy
54,235
+5,281
+11% +$242K ﹤0.01% 2542
2020
Q3 		$1.64M Sell
48,954
-2,090
-4% -$59.7K ﹤0.01% 2781
2020
Q2 		$1.22M Sell
51,044
-6,218
-11% -$148K ﹤0.01% 2985
2020
Q1 		$1.31M Buy
57,262
+23,581
+70% +$583K ﹤0.01% 2787
2019
Q4 		$954K Buy
33,681
+9,086
+37% +$229K ﹤0.01% 3270
2019
Q3 		$529K Buy
+24,595
New +$686K ﹤0.01% 3504

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon's STOK Position: Q2 2026 in Review

Bank of New York Mellon increased its Stoke Therapeutics (STOK) stake by 15% in Q2 2026, buying an estimated $670K and bringing the position to 164,273 shares worth $5.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Bank of New York Mellon first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 63 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Bank of New York Mellon held 164,273 shares of Stoke Therapeutics worth $5.38M as of Q2 2026.
  • Bank of New York Mellon bought 20,866 Stoke Therapeutics shares in Q2 2026, an estimated $670K.
  • Stoke Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2401 holding.
  • Bank of New York Mellon first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 63 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.